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Abstract
Background: For the past two decades, chlamydia has been the most commonly notified infectious disease
among young people (15–29 year olds) in Australia, the United States of America and the United Kingdom and
rates have increased annually in these three countries. In Australia, rates of chlamydia are three times higher in
Aboriginal compared with non-Aboriginal people. Australian sexually transmissible infection guidelines recommend
annual chlamydia testing for 15–29 year old females and males. This analysis will examine the incidence and
predictors of annual chlamydia testing in 15–29 year olds attending four Aboriginal Community Controlled Health
Services (ACCHS) in Australia.
Methods: From 2009–2011, attendance and chlamydia testing data were extracted from the patient system to calculate
the number and proportion of 15–29 year olds that were tested for chlamydia and that tested positive for chlamydia by
gender (male, female), age-group (15–19, 20–24, 25–29 years), Aboriginal status (Aboriginal, non-Aboriginal people) and
by the four ACCHSs sites (1, 2, 3 and 4). A cohort was created to calculate the incidence rate per 100 person-years (PY)
and predictors of an annual chlamydia test (a test within 12-months of a previous test/visit) by the above factors using
Cox regression. Unadjusted and adjusted hazard ratios (AHR) and their 95 % confidence intervals (CIs) and p-values were
calculated with significance at p < 0.05.
Results: From 2009–2011, there were 2896 individuals who attended the four ACCHSs. Overall , 17 % (22 % of females
and 10 % of males) were tested for chlamydia and 9 % tested positive (8 % of females and 14 % of males). The median
time to an annual chlamydia test was 10.7 months. The cohort included 2318 individuals. Overall the incidence rate of
an annual chlamydia test was 9.1 per 100 PY (11.6 in females and 5.8 in males). Predictors of an annual chlamydia test
were being female (AHR: 1.7, 95 % CI: 1.2-2.2, p < 0.01), being 15–19 years old (AHR: 1.6, 95 % CI: 1.1-2.3, p < 0.01) and
attending ACCHS site 2 (AHR: 3.8, 95 % CI: 1.8-8.0, p < 0.01).
Conclusions: This analysis highlights that opportunistic STI testing strategies are needed to increase annual chlamydia
testing in young people; especially males.
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Background
Chlamydia is a sexually transmissible infection (STI) and
for the past two decades it has been the most commonly
notified infectious disease among young people in
Australia [1], the United States of America (US) [2], the
United Kingdom (UK) [3] and New Zealand [4]. In
Australia, chlamydia notification rates are higher in fe-
males, 15–29 year olds and those living in regional and re-
mote areas [1]. Chlamydia notification rates are three
times higher among Aboriginal and Torres Strait Islanders
(hereafter ‘Aboriginal’) compared with non-Aboriginal
people in Australia and rates are increasing [1, 5]. Higher
rates of chlamydia have also been reported among Indigen-
ous compared with non-Indigenous people in Canada, the
US and New Zealand [4, 6, 7]. Reasons for these higher
rates could be attributed to lower access to primary health
care services, and cultural and social determinants of
health [8].
An estimated 85 % of chlamydia infections are asymp-
tomatic and as a result regular STI testing is an import-
ant prevention strategy to detect and treat infection
early, reduce poor health outcomes from developing and
to prevent transmission to others [9]. Untreated chla-
mydia infection can lead to pelvic inflammatory disease
and infertility [10, 11]. STI guidelines in the US [2] and
the UK [3] recommend annual chlamydia testing of 16–
24 year old females; however Australian STI guidelines
recommend annual chlamydia testing of 15–29 year old
females and males [12].
To decrease the prevalence of chlamydia, modelling
studies in Australia and the UK have suggested that an
annual chlamydia testing rate of 30 % or greater among
15–24 year old females is needed [13, 14]. However, a
modelling study conducted in remote Aboriginal com-
munities in Australia, where chlamydia is endemic sug-
gested an annual chlamydia testing rate of 60 % or
greater would be required to reduce the prevalence of
chlamydia by 9 % [15].
Primary health care centres are recognised as playing an
important role in STI testing, treatment and management
[16, 17]. In Australia, Aboriginal Community Controlled
Health Services (ACCHS) provide culturally appropriate
primary health care to Aboriginal people with an esti-
mated 142 ACCHSs across Australia and 42 in the state of
New South Wales (NSW) [18]. A community-based sur-
vey of 16–30 year old Aboriginal people in NSW found
that greater than 50 % of participants preferred to receive
STI testing, treatment and education at an ACCHSs
compared with non-Aboriginal primary health care
services and sexual health clinics [17]. This highlights
that ACCHS are the preferred health care provider
for young Aboriginal people in NSW.
A cross-sectional study of 16–29 year olds attending
non-Aboriginal primary health care centres in Australia
found that 8 % were tested for chlamydia, with higher test-
ing rates in females than males (12 % vs 4 %, p < 0.01)
[16]. However this cross-sectional study cannot determine
if the same people are tested every year or if different
people are being tested. To more accurately examine an-
nual chlamydia testing of the same person, we used a lon-
gitudinal study design to estimate the incidence and
predictors of an annual chlamydia test among 15–29 year
olds who attended four ACCHSs in NSW Australia.
Methods
The aboriginal population
In 2014, the Australian Institute of Health and Welfare
(AIHW) estimated that there were 713,600 Aboriginal
people in Australia which accounted for 3 % of the Aus-
tralian population [8]. The number of Aboriginal people
varied across the Australian jurisdictions with the largest
estimated population residing in NSW (220,902) [8].
Nationally, the median age of the Aboriginal population
is 21 years compared with 37 years for the non-
Aboriginal population [8]. Aboriginal compared with
non-Aboriginal people have higher rates of chronic and
other communicable diseases, higher rates of unemploy-
ment; lower levels of home ownership, school completion
and life expectancy [8]. To reduce the disparity between
Aboriginal and non-Aboriginal people the Australian gov-
ernment has released a number of national strategies in-
cluding the Fourth National Aboriginal and Torres Strait
Islander Blood-Borne Viruses (BBV) and Sexually Trans-
missible Infections (STI) Strategy, 2014–2017 [19].
This study was conducted prior to the implementation
of a sexual health quality improvement (QIP) project
commencing in four ACCHSs in NSW known as SHIM-
MER [20]. SHIMMER aimed to increase STI (chlamydia,
gonorrhoea, syphilis, HIV) and hepatitis (hepatitis B and
C) testing and improve the management of these infec-
tions. To assist in achieving the aims of SHIMMER, this
longitudinal analysis was conducted to assist in develop-
ing STI testing and management strategies. The QIP
used in SHIMMER commenced in March 2012. This
analysis focusses on chlamydia because it has the highest
prevalence among young Aboriginal people and because
we wanted to use chlamydia as a starting point to de-
velop the STI testing and management strategies and
then slowly add other testing strategies that would ad-
dress the other infections.
SHIMMER was conducted in collaboration with
four ACCHSs in NSW to ensure Aboriginal people
were included in the decision making process, main-
tained ownership of their data and were integral to
the implementation of the SHIMMER project. The
four ACCHSs varied in size and scope of medical, al-
lied health and health education services provided to
local Aboriginal communities. They were all located
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in regional areas of NSW and serviced different Abo-
riginal communities. The four ACCHSs were located large
distances from each other to limit the possibility of young
people attending multiple ACCHSs. They also had inde-
pendent management and protocols for medical and allied
health services provided to the local Aboriginal
communities.
Data extraction
A data extraction tool called the ‘GeneRic Health Net-
work Information Technology for the Enterprise’
(GRHANITE™) [21] was installed onto the electronic pa-
tient system at the four ACCHSs. GRHANITE™ extracted
de-identified patient attendance and STI testing data
through the internet. Only medical consultations with a
doctor or nurse were included, with allied health consulta-
tions such as dental and physiotherapy excluded.
Statistical analysis
Data from 2009–2011 were used to calculate the follow-
ing among 15–29 year olds:
1. The number and proportion of individuals that
attended (attendance) by the following factors:
a. Gender (female, male)
b. Age-group (15–19, 20–24, 25–29 years)
c. Aboriginal status (Aboriginal, non-Aboriginal)
d. ACCHS site (1,2,3 and 4)
2. The number and proportion of individuals who were
tested for chlamydia by the above mentioned factors
(repeat visits and tests of the same person were
remove - proportion tested overall).
3. The number and proportion of individuals who
tested positive overall by the above mentioned
factors (repeat positives and tests of the same person
were removed -positivity).
4. The proportion of individuals who were tested at
least once for chlamydia in each year (in 2009 and in
2010 and in 2011) by gender (repeat tests and visits
of the same person within a 12-month period were
removed) - proportion tested annually).
We used a chi-squared test with statistical significance
at p < 0.05 to assess if there were any differences in chla-
mydia testing in females and males by the above men-
tioned factors
We then created a cohort to assess the incidence
rate of an annual chlamydia test and predictors of an
annual chlamydia test from 2009–2011. An annual
chlamydia test was defined as a test within 12-
months of a previous test/visit. Those aged 15–29
years entered the cohort at their first chlamydia test
in 2009 or if not tested in 2009, then those who
attended from 1st January 2010. We selected this date
because national STI guidelines in Australia recommend
annual chlamydia testing of 15–29 year olds [12] and
to ensure twelve-months had passed since their previ-
ous chlamydia test. If a person was 29 years old when
they entered the cohort in 2009 or 2010, they stayed
in the cohort until they were tested even if they
turned 30 year olds.
Using this cohort we calculated the following among
15–29 year olds:
1. The incidence rate of annual chlamydia testing per
100 person-years (PY) overall and by the above
mentioned factors and by Year (in 2010 and in
2011 – incidence rate of annual chlamydia testing)
2. The predictors of annual chlamydia testing by the
above mentioned factors – predictors of annual
chlamydia testing)
To examine the predictors of annual chlamydia testing
we used univariate and multivariate Cox regression. The
regression analysis was restricted to the variables that
were collected by GRHANITETM. Unadjusted and ad-
justed hazard ratios (HR) and their 95 % confidence in-
tervals (CIs) and p-values were calculated with statistical
significance at p < 0.05.
Data were analysed using STATA 12 statistical soft-
ware (STATA Corporation, College Station TX).
Ethical approval
The SHIMMER project received ethical approval from
the Aboriginal Health & Medical Research Council of
NSW and the University of New South Wales Human
Research Ethics Committee. We also received approval
from each participating ACCHSs Boards and signed
agreements with each ACCHSs detailing issues such as
confidentiality, privacy, consent, use of patient data,
publications, and roles and responsibilities. The SHIM-




From 2009–2011, 2896 individuals aged 15–29 years
attended the four ACCHSs. A higher proportion were
aged 15–19 years (38 %), Aboriginal (81 %) and attended
ACCHSs site 3 (41 %, Table 1).
Proportion tested overall
Overall, 17 % of individuals were tested for chlamydia,
22 % of females and 10 % of males (p < 0.01, Table 1).
Among males, a higher proportion of 15–19 year olds
(12 %) were tested for chlamydia compared with the
other two age-groups; however this was not statistically
significant (p = 0.14). A higher proportion of Aboriginal
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compared with non-Aboriginal males were tested (11 %
vs 5 %, p < 0.01). Among females, a higher proportion
of 20–24 year olds (26 %) were tested for chlamydia
compared with the other two age-groups (Table 1);
however this was not statistically significant (p = 0.07)
and a greater proportion of Aboriginal females com-
pared with non-Aboriginal females were tested (24 %
vs 17 %, p < 0.01).
Proportion tested annually
The proportion of individuals tested for chlamydia in
each year of the study was similar; from 7 % in 2009 to
6 % in 2010 and 8 % in 2011. Among females, 9 % were
tested in 2009, 10 % in 2010 and 10 % in 2011and
among males, 3 % were tested in 2009, 2 % in 2010 and
7 % in 2011.
Incidence rate of an annual chlamydia test
A total of 2318 individuals were included in the cohort
and the median time from entering the cohort to a chla-
mydia test was 10.7 months. Overall, the incidence rate
of an annual chlamydia test per 100PY was 9.1; higher in
females, 20–24 year olds, Aboriginal people and those
who attended ACCHSs site 3 (Table 2). Among females
and males, the highest rate of an annual chlamydia test
was in 20–24 year olds (Figs. 1 and 2).
Predictors of annual chlamydia testing
Independent predictors of an annual chlamydia test were
being female, being 15–19 year olds, and attending
ACCHS site 2 (Table 2).
Positivity
Over the three-year period, there were 495 individual
chlamydia tests with 9 % testing positive (Table 1). Al-
though a higher number of positive chlamydia tests were
in females than males (30 vs 17), a higher proportion of
males than females tested positive (14 % vs 8 %, Table 1).
Among males, the highest positivity was in 15-19 year
olds (16 %) compared with the other two age-groups
and in females, positivity was highest in 15–19 year olds
(15 %, Table 1).
Discussion
This study found that 17 % of young people were tested
for chlamydia over a three-year period and 9 % had an
annual chlamydia test. Although a higher number of fe-
males than males tested positive for chlamydia a higher
proportion of males than females tested positive. Inde-
pendent predictors of an annual chlamydia test were be-
ing female, being 15–19 years old and attending ACCHS
site 2.
A strength of this study was that it examined chla-
mydia testing by using routinely collected attendance
and STI testing data from the electronic patient system
at four ACCHSs which provided a large sample size for
the analysis. There are a number of limitations of our
study including; attendance and chlamydia testing data
that were not entered into the electronic patient record
system were excluded. It is possible that some indivi-
duals may have undergone repeat testing at non-
Aboriginal primary health care centres; therefore we
may have under-estimated annual testing rates. The re-
gression analysis did not include the testing of other
STIs which could have been a factor in predicting chla-
mydia testing. GRHANITETM could not extract the rea-
son why young people attended the ACCHS and this
Table 1 Number and proportion tested for chlamydia and






n (%) n (%) n (%)
Overall 2896 (100) 495 (17) 47 (9)
Males
1223 (42) 119 (10) <0.01 17 (14)
Age-group (years)
15-19 481 (39) 56 (12) 0.14 9 (16)
20-24 354 (29) 33 (9) 4 (12)
25-29 388 (32) 30 (8) 4 (13)
Aboriginal status
Aboriginal 1023 (84) 110 (11) <0.01 15 (14)
Non-Aboriginal 200 (16) 9 (5) 2 (22)
ACCHS site
1 220 (18) 5 (2) <0.01 0 (0)
2 178 (15) 27 (15) 4 (15)
3 514 (42) 77 (15) 12 (15)
4 311 (25) 10 (3) 1 (10)
Females
1673 (58) 376 (22) 30 (8)
Age-group (years)
15-19 605 (36) 130 (21) 0.07 20 (15)
20-24 578 (35) 148 (26) 8 (5)
25-29 490 (29) 98 (20) 2 (2)
Aboriginal status
Aboriginal 1323 (79) 316 (24) <0.01 27 (9)
Non-Aboriginal 349 (21) 60 (17) 3 (5)
ACCHS site
1 402 (24) 16 (4) <0.01 3 (18)
2 204 (12) 42 (20) 5 (12)
3 673 (40) 249 (37) 17 (7)
4 394 (24) 69 (17) 5 (7)
*p-value with significance at p < 0.05
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could have influenced the predictors of chlamydia test-
ing. We were not able to identify those individuals who
were residents of the local Aboriginal communities com-
pared with visitors to the Aboriginal communities; which
could result in our study under-estimating annual chla-
mydia testing rates as local residents are able to return
annually to be tested compared to visitors to the
communities.
In our study, the incidence rate of an annual chlamydia
test in females was 11.6 per 100PY. Two other longitu-
dinal studies have examined the incidence rate of an
annual chlamydia test in females; one in the US and an-
other in Australia [22, 23]. The US study found that the
incidence rate of an annual chlamydia test ranged from
2.1 per 100 woman-years in 15–19 year old females to
13.5 per 100 woman-years in 25 year old females [22] and
the Australian study found the incidence rate of an annual
chlamydia test was 4.4 per 100 woman-years in 16–29
year old females attending primary health care centres
and sexual health clinics [23]. Overall, the annual testing
rate in our study was higher compared with the US and
other Australian study.
Table 2 Incidence rates and predictors of chlamydia testing in 15–29 year olds, 2009-2011
Demographic factors, year and
ACCHS site






Female 11.6 (10.1-13.3) 1.5 (1.1-1.9) <0.01 1.7 (1.2-2.2) <0.01
Male 5.8 (4.6-7.3) 1 - 1 -
Age-group (years)
15-19 9.0 (7.4-11.0) 1.3 (0.9-1.8) 0.06 1.6 (1.1-2.3) <0.01
20-24 11.0 (9.1-13.2) 1.2 (0.9-1.6) 0.24 1.3 (0.9-1.8) 0.11
25-29 7.1 (5.6-9.1) 1 1
Aboriginal status
Aboriginal 9.7 (8.6-11.1) 1.1 (0.8-1.6) 0.50 1.2 (0.9-1.8) 0.05
Non-Aboriginal 6.3 (4.5-8.8) 1 - 1 -
ACCHS site
1 1.1 (0.5-2.2) 1.6 (0.7-3.5) 0.25 1.6 (0.7-3.6) 0.22
2 13.6 (10.4-17.8) 3.4 (1.6-7.1) 0.01 3.8 (1.8-8.0) <0.01
3 14.0 (12.0-16.4) 2.0 (0.9-4.4) 0.07 2.2 (0.9-4.7) 0.05
4 7.6 (5.9-9.8) 1 1
aIncidence rate per 100 person-years, bHazard ratio and 95 % confidence interval, *p-value – significance at p < 0.05
Fig. 1 Incidence rate and 95 % confidence intervals of chlamydia testing in females by age-group, 2009-2011
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Being female was an independent predictor of having
an annual chlamydia test in our study. Higher chlamydia
testing rates in females compared with males has been a
common finding in a number of other studies [16, 24].
One factor influencing this could be the types of consul-
tations that females are having, such as reproductive
health consultations (contraception, Pap smear, preg-
nancy). A study conducted in primary health care centres
in Australia found that reproductive health consultations
were highly associated with chlamydia testing [16]. To in-
crease chlamydia testing in males the ACCHS could in-
clude chlamydia testing in adult health checks (AHCs) if
not already included. AHC are a general health assess-
ment offered in ACCHS [25]. For every completed AHC
the ACCHS can receive $212 from the Australian govern-
ment’s Medicare Benefits Scheme. A completed AHC can
be charged every nine-months [25]. A clinical audit was
undertaken in the SHIMMER project which highlighted
that 50 % of AHCs among young males included a chla-
mydia test; however only 16 % of the males were offered
an AHC [26]. Offering more AHC could be an effective
STI testing strategy to increase chlamydia testing in young
males and among females who are not attending for re-
productive health reasons.
In our study, 9 % of 15–29 year olds had an annual
chlamydia test. The importance of regular chlamydia
testing is highlighted by three factors; that chlamydia
re-infection is common (~22 %) [27], that 85 % of
chlamydia infections are asymptomatic [9] and that
among those females who had untreated chlamydia
infection, 10 % developed pelvic inflammatory disease
with 12-months [28]. As chlamydia re-infection is
common annual chlamydia testing is an important
prevention strategy with Australian STI guidelines
recommending a re-test for chlamydia three-months
after being diagnosed [12]. These factors highlight the
importance of developing STI testing strategies for
young people that will identify new infections early
and provide treatment and education.
Conclusions
This analysis highlights that opportunistic STI testing
strategies could be used by the ACCHSs to increase an-
nual chlamydia testing in young attendees; especially
males.
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